Reported Saturday, Lilly Presents Phase 1 AJX-101 Data At EHA 2026 Showing First-In-Class Type II JAK2 Inhibitor Delivers 70% Spleen Volume Reduction And Symptom Improvement In Myelofibrosis

뉴스 본문을 불러오고 있어요.

Reported Saturday, Lilly Presents Phase 1 AJX-101 Data At EHA 2026 Showing First-In-Class Type II JAK2 Inhibitor Delivers 70% Spleen Volume Reduction And Symptom Improvement In Myelofibrosis | 웨이프 WAPE

Reported Saturday, Lilly Presents Phase 1 AJX-101 Data At EHA 2026 Showing First-In-Class Type II JAK2 Inhibitor Delivers 70% Spleen Volume Reduction And Symptom Improvement In Myelofibrosis

기사 요약

관련 종목

댓글 —